Patients will received Tekmira's TKM-Ebola

The Food and Drug Administration has authorized Tekmira Pharmaceuticals Corp. (Nasdaq: TKMR) to provide TKM-Ebola to treat patients with confirmed or suspected Ebola infections. The stock price surged $2.95 to $23.11.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.